Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on IPSEN. We currently have 4 research reports from 1 professional analysts.
|10Nov16 01:30||PRN||IPSEN to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 16th, 2016|
|10Nov16 01:00||PRN||International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2016|
|26Oct16 02:00||PRN||Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the 2016 Annual Meeting of the Child Neurology Society|
|19Oct16 01:00||PRN||Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the Annual Meeting of the American Academy of Physical Medicine & Rehabilitation|
|30Sep16 02:05||PRN||Ipsen Biopharmaceuticals, Inc. Announces Nine Poster Presentations at the 2016 North American Neuroendocrine Tumor Society (NANETS) Symposium|
|21Sep16 06:54||PRN||Ipsen Announces Data Presentation for Dysport® (abobotulinumtoxinA) at American Academy of Cerebral Palsy and Developmental Medicine|
|03Aug16 08:37||PRN||Multimedia Assets Now Available: Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients aged two and older|
Frequency of research reports
Research reports on
Q1 negatively impacted by RoW
28 Apr 16
Q1 sales grew 4.7% at CER and 3.4% as reported, including +9.7% at CER for speciality care and -11% for primary care. Sales increased by 74.7% at CER in North America (c.15% of total sales) and by 3.7% in major Western European countries (39% of total sales). The significant decrease in the RoW accounts for 24% of total sales (-16.1% at CER and -18.6% as reported).
07 Mar 16
1/ Q4 sales were up 21.3% at CER (FY15 +10.4%). Operating income increased by 10.2% and the group’s net income by 23.7%. Operating cash flow decreased by 9% to 15.5% of sales (vs. 19.3% in FY14). 2/ Management announced the in-licensing of the global rights ex North America and Japan of cabozantinib for the second-line treatment of advanced renal cell carcinoma, for which commercial launch is expected in 2017 in Europe.
Strong Somatuline and progress in neuro-endocrine studies
04 Aug 15
1/ Q2 sales increased by 9.3% (+4.5% at CER). H1 increase was 11.8% (+7.9% at CER). H1 current operating income increased by 3.2%. Operating CF fell by 33.8% (+11.2% before changes in working capital). 2/ Ipsen’s partner, Lexicon Pharmaceuticals, announced positive results from the TELESTAR phase 3 study showing that telotristat etiprate is effective in the treatment of carcinoid syndrome caused by neuroendocrine tumors not adequately controlled by somatostatin analogs
30 Nov 16
Abzena (ABZA): Interim results indicate happy customers (BUY) | Horizonte Minerals* (HZM): Fund raise completed (CORP) | SacOil* (SAC): Half-year trading statement (CORP) | Revolution Bars (RBG): New openings (BUY) | Amino Technologies* (AMO): Multi operator FUSION roll out (CORP)
N+1 Singer - Morning Song 30-11-2016
30 Nov 16
Sanderson has delivered full year results in line with expectations and the 19 October trading update after a strong finish to the year compensated for a slower start. A healthy level of pre-contracted recurring revenue (50%), incremental sales to existing customers and new customer wins at higher average order values helped deliver solid revenue growth in both the Digital Retail (+9%) and Enterprise (+12%) divisions. A decent order book and good sales momentum suggest that the company is on track to deliver on unchanged profit expectations for the current year. We continue to view the valuation (FY17 EV/EBITDA 8.6x) as undemanding given an attractive combination of accelerating growth potential, strong cash generation and growing dividends.
N+1 Singer - Morning Song 29-11-2016
29 Nov 16
Vp has reported another impressive set of interims, confirming strong growth in most markets and a positive outlook. Recent acquisitions are bedding in well and the full year outturn is set to exceed previous expectations (5%/6% EPS upgrades in FY17/FY18). The recent Capital Markets Day provided a reminder of Vp’s qualities (specialist focus, high returns, strong cash generation) and its growth potential, which in our view are not reflected in a modest <11x P/E rating. We firmly believe the shares are due a re-rating and see intrinsic value in excess of 800p.
Food intolerance driving growth
29 Nov 16
Omega Diagnostics Group has an established core business providing high quality in vitro diagnostic tests within three core areas of competence – Food Intolerance, Allergy & Autoimmune, Infectious Disease – that are sold in over 100 countries. The group offers steady low single-digit growth which is profitable and cash generative. Investment in new products has seen the launch of a new panel of automated allergy tests and progress on Visitect CD4 for monitoring of HIV positive patients. Interim results highlighted the opportunities to accelerate growth of the business, particularly Allersys, which has drawn attention from its partner.
Small Cap Breakfast
29 Nov 16
Asia Pacific Investment Partner - the research-driven emerging and frontier markets real estate development business intends to float on AIM and conduct a placing in December RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m Diversified Oil & Gas— Schedule One now out. $60m to be raised. Expected admission 6 December. Creo Medical Group —UK based medical device company focused on surgical endoscopy, a recent development in minimally invasive surgery. Admission due 7 December. Fundraising details TBA.